Clinical Trial Update: Targeted Natural Killer (NK) Cell Based Adoptive Immunotherapy for the Treatment of Patients With Non-Small Cell Lung Cancer (NSCLC) After Radiochemotherapy (RCT) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating targeted natural killer (NK) cell adoptive immunotherapy after radiochemotherapy in patients with non-small cell lung cancer (…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Targeted Natural Killer (NK) cell based adoptive immunotherapy

Snippet

Sponsor: Technical University of Munich | Conditions: NSCLC Stage IIIA/B | Phase 2 | Status: COMPLETED